

General Anesthesia Drugs Market to Exceed \$7.7 Billion: North America Leads with Strong R&D, Regulatory Approvals

PORTLAND, OR, UNITED STATES, October 9, 2024 /EINPresswire.com/ --The global general anesthesia drugs market is set to grow significantly, driven by rising demand and advances in healthcare. Below is an in-depth analysis of the market's key drivers, segments, and regional outlook.


https://www.alliedmarketresearch.com /request-sample/5627

Market Overview

• 2021 Market Size: \$5.4 billion

• 2031 Market Projection: \$7.7 billion

CAGR: 3.5% from 2022 to 2031



General Anesthesia Drugs Market size, share, demand

Key Drivers

- Prevalence of Chronic Diseases: Rise in cases of cancer, cardiovascular diseases, and osteoarthritis increases demand for general anesthesia drugs, especially in surgeries.
- · Surgical Demand: Growing number of procedures like cardiac surgeries, hip and knee replacements, and cancer surgeries.
- Government and Private Funding: Investments in R&D for anesthesia drug formulation and improvements in pharmaceutical manufacturing.
- Approvals and New Drug Launches: FDA approval of drugs like propofol injectable emulsion in 2020 boosts market growth.

Major Challenges

• Side Effects: Nausea, vomiting, and allergic reactions may limit the adoption of general anesthesia drugs.

Market Segmentation

- · By Drug Type:
- Leading Segment (2021): "Others" (includes ketamine, thiopental, etc.)
- High Growth: Sevoflurane due to increased demand for inhalation anesthesia.
- By Route of Administration:
- Top Contributor: Inhalation anesthesia driven by diagnostic procedures.
- Rising Segment: Intravenous anesthesia due to open-heart surgeries.
- By Surgery Type:
- Leading: Knee and hip replacements (due to osteoarthritis and injury prevalence).
- · Growth: Heart surgeries, owing to the rise in cardiovascular disease.
- By End User:
- Top Market: Hospitals (dominate due to number of facilities and government expenditure).
- Growth: Ambulatory surgical centers as more patients prefer outpatient procedures.

Regional Insights

- North America: Dominates due to high chronic disease prevalence, regulatory approvals, and R&D activities.
- Asia-Pacific: Fastest-growing region (CAGR of 4.2%), driven by increased surgical procedures and healthcare expenditures.

Key Players

• AbbVie, AstraZeneca, Baxter International Inc., Pfizer, and Hikma Pharmaceuticals PLC are among the prominent companies in the general anesthesia drugs market.

DDDDDDD DDDDDD: https://www.alliedmarketresearch.com/purchase-enquiry/5627

David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social media: Facebook

Χ

This press release can be viewed online at: https://www.einpresswire.com/article/750250567

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.